Nicotinamide Mononucleotide Adenylyl Transferase 2: A Promising Diagnostic and Therapeutic Target for Colorectal Cancer

Abstract EN

Colorectal cancer (CRC) is one of the most common cancers all over the world.

It is essential to search for more effective diagnostic and therapeutic methods for CRC.

Abnormal nicotinamide adenine dinucleotide (NAD) metabolism has been considered as a characteristic of cancer cells.

In this study, nicotinamide mononucleotide adenylyl transferases (NMNATs) as well as p53-mediated cancer signaling pathways were investigated in patients with colorectal cancer.

The CRC tissues and adjacent normal tissues were obtained from 95 untreated colorectal cancer patients and were stained for expression of nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2) and p53.

The survival rate was analyzed by the Kaplan-Meier method and the log-rank test.

The multivariate Cox proportional hazard regression analysis was conducted as well.

Our data demonstrated that expression of NMNAT2 and p53 was significantly higher in CRC tissues, while NMNAT2 expression is in correlation with the invasive depth of tumors and TNM stage.

Significant positive correlation was found between the expression of NMNAT2 and the expression of p53.

However, NMNAT2 expression was not a statistically significant prognostic factor for overall survival.

In conclusion, our results indicated that NMNAT2 might participate in tumorigenesis of CRC in a p53-dependent manner and NMNAT2 expression might be a potential therapeutic target for CRC.